Hybridoma technology is the bedrock of antibody discovery, merging immunized cells to generate monoclonal antibodies. This ensures consistency, high specificity, and high yield for therapeutic and diagnostic applications.
Single B cell screening represents a breakthrough in antibody discovery. Using state-of-the-art technology to isolate, sequence, and analyze individual B cells, ensuring precise identification of specific antibodies for novel treatments.
F2 Building, Yizhuang Biomedical Park, No. 88, Kechuang Six Street, Beijing. P.R. China. 101111.
© 2023 Kyinno Biotechnology | Site Credits | Privacy Policy | Accessibility Policy | Sitemap